So many myths & misconceptions

Myth 8: "Testosterone Causes Aggression"

Although anabolic steroids can increase aggression, T therapy does not elicit such behavior. In fact, there's significant evidence suggesting that estrogens, not T, play a significant role in aggression and hostility. Testosterone therapy has been reported to decrease aggression, irritability, and anxiety in over 90% of patients treated for symptoms of testosterone deficiency. Thus, it's a fact that testosterone therapy decreases anxiety, irritability, and aggression.

Myth 9: "Testosterone May Increase the Risk of Breast Cancer"

Historically, testosterone (T) has been recognized as antagonistic to estrogen and has been used in the treatment of estrogen-sensitive conditions, including breast cancer. While some studies have reported an association between elevated testosterone and breast cancer, these are often plagued with methodological limitations and fail to account for associated elevated estradiol (E2) levels and increased body mass index. In fact, testosterone receptor (AR) signaling has been shown to exert a growth-inhibiting, pro-apoptotic, anti-estrogenic effect in normal and cancerous breast tissue.

Clinical trials have confirmed that T has a beneficial effect on breast tissue, decreasing breast proliferation and preventing stimulation from E2. It's the balance between T and E2 that is breast protective. Although T can convert to E2, having a stimulatory effect via estrogen receptor alpha, it is breast protective overall. This is demonstrated in testosterone therapy combined with an aromatase inhibitor being effectively used to treat testosterone deficiency symptoms in breast cancer survivors. Therefore, it's a fact that testosterone is breast protective and does not increase the risk of breast cancer.

Myth 10: "The Safety of Testosterone Use in Women has not been Established"

Testosterone therapy, especially non-oral forms, has a well-established safety profile in women. Testosterone implants have been used safely in women since 1938, with long-term data available on the efficacy, safety, and tolerability of doses of up to 225 mg in up to 40 years of therapy. Moreover, studies on 'female to male' transgender patients receiving supra-pharmacologic doses have reported no increase in mortality, breast cancer, vascular disease, or other major health problems.

Many side effects and safety concerns attributed to T come from oral formulations, or are secondary to increased aromatase activity leading to elevated E2. Aromatase activity increases with age, obesity, alcohol intake, insulin resistance, breast cancer, certain medications, a processed diet, and a sedentary lifestyle. Monitoring aromatase activity and symptoms of elevated E2 is critical to the safe use of T in both sexes. Thus, it's a fact that the safety of non-oral testosterone therapy in women is well established, including long-term follow up.  Jason & Rita.